GSK extends its $2.6bn offer for Human Genome by 3 weeks
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has extended its unsolicited $2.6 billion bid to acquire all of the outstanding shares of its long-time partner Human Genome Sciences until the end of June, giving shareholders additional time to mull over a whether they want to hand over their shares. The HGS board has rejected the unsolicited tender offer as inadequate, and has urged shareholders not to support it.